Table 2

Concentrations of sTNFR1 and neuropeptides in serum

Variable

Early RA (pg/ml)

Long-standing RA (pg/ml)

P

Controls (pg/ml)

sTNFR1

1500^a

1900^b

ns

1200^d

(1300–1700)

(1600–2000)

BN/GRP

3000^a

1700^b

<0.05

340^e

(2400–3300)

(430–2500)

CGRP

1500^a

820^b

ns

310^e

(1100–1600)

(510–1600)

NPY

610^a

900^c

ns

930^f

(370–890)

(700–1900)

SP

170^a

410^b

<0.05

180^g

(150–300)

(320–440)

VIP

250^a

280^b

ns

290^g

(210–280)

(230–340)

ESR

20^a

32^b

ns

nm

(7 – 32)

(22 – 47)

Concentrations were measured using ELISA. Values are medians (and Q₁–Q₃). The ESR is also shown. P relates to long-standing RA versus early RA. ^an = 4; ^bn = 22; ^cn = 21; ^dsTNFR1 value in healthy controls according to the manufacturer; ^en = 4; ^fn = 2; ^gn = 11. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; nm, not measured; ns, not significant; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.

Grimsholm et al. Arthritis Research & Therapy 2005 7:R416   doi:10.1186/ar1503